德国大型遗传性听力损失队列中人工耳蜗植入结局的变异性
本研究纳入德国123只植入耳(76例先证者)的遗传性听力损失人工耳蜗植入者,按ACMG/AMP指南明确遗传病因并记录术后听力学结局。结果显示影响耳蜗神经成分的基因突变与较差表现相关,支持「螺旋神经节假说」。
要点
- 影响耳蜗感觉非神经结构的致病性变异者,言语表现达到或高于所有耳的中位水平70%。
- 螺旋神经节表达基因的突变较所有临床参数更显著地负向影响人工耳蜗植入结局。
- 遗传因素可解释部分人工耳蜗植入结局变异,神经表达基因是最强单一类别。
核心结论
- 对德国大型人工耳蜗植入者队列的遗传病因与植入结局分析显示显著变异性,影响耳蜗神经成分的基因突变与较差表现相关,支持「螺旋神经节假说」。
研究设计与样本
- 本研究纳入德国大型人工耳蜗植入者队列(123只植入耳;76例先证者),按美国医学遗传学与基因组学学会(ACMG)/分子病理学协会(AMP)指南明确遗传性听力损失病因,并记录术后听力学结局。
- 所有患者接受术前临床和听力学检查;术后结局基于语后听力损失发病(>6岁)患者至少1年、先天性或语前/围产期听力损失发病(≤6岁)儿童5年的术后听力学随访。
- 遗传分析基于三种方法:单基因筛查、针对已知综合征性和非综合征性听力损失基因的定制听力损失基因面板测序、全基因组测序。
主要发现
- 76例先证者的遗传诊断涉及35个基因和61种不同的临床相关(致病性、可能致病性)变异。
- 就植入耳(n=123)而言,六个最常受累基因影响近一半植入耳:GJB2(21%;n=26)、TMPRSS3(7%;n=9)、MYO15A(7%;n=8)、SLC26A4(5%;n=6)、LOXHD1和USH2A(各4%;n=5)。
- 影响感觉非神经结构的致病性变异携带者,其言语表现达到或高于所有耳的中位水平70%(65 dB SPL安静环境下单音节词识别得分)。
- 将基因表达类别与人口学和临床类别比较(共比较30个类别),螺旋神经节表达基因的突变成为较所有临床参数更显著负向影响人工耳蜗植入结局的因素。
- 对缩减的遗传和临床类别集(n=10)进行方差分析,识别出五个导致较差表现的有害因素,效应高度显著(p<0.001),共解释观察变异的11.8%;最强单一类别为神经基因表达,解释变异的3.1%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The variability in outcomes of cochlear implantation is largely unexplained, and clinical factors are not sufficient for predicting performance. Genetic factors have been suggested to impact outcomes, but the clinical and genetic heterogeneity of hereditary hearing loss makes it difficult to determine and interpret postoperative performance. It is hypothesized that genetic mutations that affect the neuronal components of the cochlea and auditory pathway, targeted by the cochlear implant (CI), may lead to poor performance. A large cohort of CI recipients was studied to verify this hypothesis. DESIGN: This study included a large German cohort of CI recipients (n = 123 implanted ears; n = 76 probands) with a definitive genetic etiology of hearing loss according to the American College of Medical Genetics (ACMG)/Association for Molecular Pathology (AMP) guidelines and documented postoperative audiological outcomes. All patients underwent preoperative clinical and audiological examinations. Postoperative CI outcome measures were based on at least 1 year of postoperative audiological follow-up for patients with postlingual hearing loss onset (>6 years) and 5 years for children with congenital or pre/perilingual hearing loss onset (≤6 years). Genetic analysis was performed based on three different methods that included single-gene screening, custom-designed hearing loss gene panel sequencing, targeting known syndromic and nonsyndromic hearing loss genes, and whole-genome sequencing. RESULTS: The genetic diagnosis of the 76 probands in the genetic cohort involved 35 genes and 61 different clinically relevant (pathogenic, likely pathogenic) variants. With regard to implanted ears (n = 123), the six most frequently affected genes affecting nearly one-half of implanted ears were GJB2 (21%; n = 26), TMPRSS3 (7%; n = 9), MYO15A (7%; n = 8), SLC26A4 (5%; n = 6), and LOXHD1 and USH2A (each 4%; n = 5). CI recipients with pathogenic variants that influence the sensory nonneural structures performed at or above the median level of speech performance of all ears at 70% [monosyllable word recognition score in quiet at 65 decibels sound pressure level (SPL)]. When gene expression categories were compared to demographic and clinical categories (total number of compared categories: n = 30), mutations in genes expressed in the spiral ganglion emerged as a significant factor more negatively affecting cochlear implantation outcomes than all clinical parameters. An ANOVA of a reduced set of genetic and clinical categories (n = 10) identified five detrimental factors leading to poorer performance with highly significant effects ( p < 0.001), accounting for a total of 11.8% of the observed variance. The single strongest category was neural gene expression accounting for 3.1% of the variance. CONCLUSIONS: The analysis of the relationship between the molecular genetic diagnoses of a hereditary etiology of hearing loss and cochlear implantation outcomes in a large German cohort of CI recipients revealed significant variabilities. Poor performance was observed with genetic mutations that affected the neural components of the cochlea, supporting the "spiral ganglion hypothesis."
引用
- Tropitzsch A, Schade-Mann T, Gamerdinger P, et al. Variability in Cochlear Implantation Outcomes in a Large German Cohort With a Genetic Etiology of Hearing Loss. Ear Hear. 2023. PMID: 37438890. doi:10.1097/AUD.0000000000001386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。